Eye Care Insider podcast

Eye Care Insider

Joshua Mali, MD

In this podcast, Joshua Mali, MD, brings you the best insights and perspectives in the field of eye care today. Through interviews with thought leaders in ophthalmology, Mali gets the inside of every story.

13 avsnitt

  • Eye Care Insider podcast

    The Doctorpreneur Series: The Secret to Saving Money with Patient Credit Card Payments with Jennifer L. Mogan

    17:03

    In this episode, Jennifer L. Mogan, MD, discusses her path into medicine, the importance of the credit card process and how it can be beneficial for eyecare practices. Welcome to another exciting episode of Eye Care insider :14 What led to the inception of the ‘Doctorpreneurship’ series? :29 About Mogan 2:16 The interview 2:47 Give us an idea of your background, your training and why you went to medicine? 3:12 How in the world did you get involved with credit card processing? 4:12 Can you summarize the whole credit card processing process? Why should eye care professional or anybody in health care be aware of this structure and how will it affect their bottom line? 5:51 So, what are you finding in the market? Are physicians aware of this, are they not? And if they’re not, how much is this potentially costing a practice? 11:37 How can they implement these strategies in practice or what services can your company offer eyecare professionals in helping to solve this problem? 12:46 Have you seen an uptake in business recently because of practices trying to minimize their expenses by lowering these rates? 13:57 How to find Mogan 14:35 What do you love about being a Doctorpreneur and do you have any advice or pearls for the audience? 15:02 Thank you, Dr. Mogan for all your great advice and tips 16:07 Jennifer L. Mogan, MD, is an anesthesiology specialist with Rochester Regional Health and a senior account specialist for Park Place Payments.   We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact Mogan by going to the company’s website, www.parkplacepayments.com or at Linkedin. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Mogan is a senior account specialist for Park Place Payments.
  • Eye Care Insider podcast

    AGTC: The New Leader in Ocular Gene Therapy with Sue Washer

    24:43

    In this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology. Welcome to another exciting episode of Eye Care insider :13 About Washer 1:51 Can you discuss what is gene therapy? How does it work on a basic level? 4:53 How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11 Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08 Is there an estimated timeline that you have for initial data read out? 14:56 You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23 What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56 Thank you so much for your insight into this fascinating topic 23:22 How to find out more about AGTC 23:31 Thank you for listening 24:15 Sue Washer, BS, MBA is the president and chief executive officer of AGTC. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company’s website at www.atgc.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.
  • Eye Care Insider podcast

    Missa inte ett avsnitt av Eye Care Insider och prenumerera på det i GetPodcast-appen.

    iOS buttonAndroid button
  • Eye Care Insider podcast

    The Secret of Successful Ophthalmic Practice Management with John B. Pinto: Part 3

    12:00

    In this episode, the third of a three-part series, John B. Pinto discusses some of the future megatrends expected for ophthalmic practices, challenge practices may face in the future, and more. Intro :13 What you think the megatrends are going to be over the next decade or so in the ophthalmic practices :50 What do you think is the most important topic or issue or challenge facing ophthalmic practices now and in the future? 4:46 If our listeners wanted to learn more, what’s the best way to contact you? 10:02 I really appreciate you and all your great advice 10:47 Any final words? 11:00 Thank you so much John, I appreciate it 11:16 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
  • Eye Care Insider podcast

    The Secret of Successful Ophthalmic Practice Management with John B. Pinto: Part 2

    18:08

    In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology. Intro :14 What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41 I’d love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35 How is the telemedicine trend going now? Is telemedicine here to stay? 11:09 Tell us about your upcoming book and your insight into it? 12:59 Stay tuned for the next episode of this special three-part miniseries 17:38 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
  • Eye Care Insider podcast

    The Secret of Successful Ophthalmic Practice Management with John B. Pinto: Part 1

    27:49

    In this episode, the first of a three-part series, John B. Pinto discusses how he got started in ophthalmic practice management, shares an historical perspective on the field, plus his advice for physicians. Intro :16 About John Pinto :54 On Pinto’s background, why he went into the ophthalmic practice management industry 1:39 Can you give listeners a historical perspective of how has ophthalmic practice management changed or evolved over the last 40 years? 7:13 What is the current state of ophthalmic practice management in America today? 13:11 Could you give a key pearl for how to handle practice management as an early- or mid-career physician as well as a late-career/ retirement-age physician? 16:02 In your experience, what would you say would be the average age of full retirement in ophthalmology? 23:56 Stay tuned for the next episode of this special three-part miniseries 27:19 John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership. UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at slackbooks.com/management. Receive 20% off with promo code PINTO20. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
  • Eye Care Insider podcast

    Alimera Sciences & Iluvien: A New Day

    25:06

    In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology. Intro :13 In this episode :18 About Rick Eiswirth :23 What’s your background? How did you get into the ophthalmology industry? 0:51 What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36 How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26 Can you tell us more about the New Day trial? 8:10 Which trial outcome would be considered a success for Iluvien? 11:58 Do you anticipate a cost savings? 13:58 What’s the status of the New Day trial? 15:15 How has COVID changed the industry landscape in ophthalmology? 16:20 Are there any new products in the pipeline? 18:38 Iluvien is approved in other countries for uveitis 20:36 What have you seen from retina specialists; are there longer efficacy rates? 22:10 What do you think is the most important challenge the ophthalmic community will face in the future? 23:17 Thanks for listening 24:36 Rick Eiswirth is president and CEO of Alimera Sciences. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.
  • Eye Care Insider podcast

    The State of Anterior Segment

    18:19

    In this episode, Cathleen M. McCabe, MD, chief medical officer of Eye Health America, shares her insights and perspectives on intraocular lenses, MIGS, dry eye and more. Intro :14 In this episode :21 About Cathleen M. McCabe, MD :28 What is your favorite intraocular lens implant to use and why? 2:24 What is your favorite minimally invasive glaucoma surgery (MIGS) to use and why? 4:03 What is your favorite dry-eye treatment to use and why? 4:49 What’s your preferred technique for secondary IOLs? 6:29 How has the role of women in ophthalmology changed throughout the years? 8:46 How did you get involved with international work? How has the pandemic affected this? 10:55 Tell us about your mission work. What are you currently involved in? 12:54 What is the most important topic/issue/challenge facing ophthalmology now or in the future? 15:11 Final words from Dr. McCabe 16:46 Cathleen M. McCabe, MD, is chief medical officer of Eye Health America; medical director of The Eye Associates and president of Outpatient Ophthalmic Surgery Society. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. To learn more about the Global Education & Research Society of Ophthalmology (or GERSO), visit https://www.gerso.org. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.
  • Eye Care Insider podcast

    Dr. Mali’s Top 5 Predictions in Ophthalmology for 2021

    19:46

    In this special episode, I sit down with this week’s co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show. Intro :14 In this episode :21 About Yasmin P. Mali, MD :35 Mali’s first prediction: The human spirit and innovation will triumph over the headline-dominating COVID-19 1:16 Yasmin Mali’s thoughts on the first predictions 2:58 Mali’s second prediction: The competition battle lines will be drawn for ocular therapeutics in the most common eye disease markets 4:04 Thoughts on the potential products in 2021 6:25 Mali’s third prediction: Increased use of artificial intelligence in clinical ophthalmology 8:18 Any advances in artificial intelligence for pediatric ophthalmology? 10:15 Mali’s fourth prediction: Telemedicine platforms will still play a role in ophthalmology 11:24 Thoughts on telemedicine in the pediatric ophthalmology community 13:44 Mali’s fifth prediction: Virtual ophthalmology conference options will remain present for the majority of 2021 15:17 Mali’s thoughts on the virtual meetings attended in 2020 17:10 Mali’s bonus announcement 18:34 Yasmin Mali’s final words 18:48 Yasmin P. Mali, MD, is a board-certified ophthalmologist and fellowship trained pediatric ophthalmologist. Mali is currently faculty at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Yasmin Mali, MD, reports no relevant financial disclosures. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.
  • Eye Care Insider podcast

    Financial Success for the Eye Care Professional

    23:05

    In this episode, I sit down with wealth management advisor Jose Segura to discuss financial planning for medical professionals. Segura will also discuss some of the better investment strategies for eye care professionals. Intro :14 In this episode :21 About Segura :30 The interview 1:30 Who is Jose Segura? 1:45 Why the focus on medical professionals and physicians? 3:45 Where should an eye care professional start regarding financial planning? 6:15 As a financial professional, what strategies do you use to help them start getting organized? 8:45 What’s the best investment? What do you tell an eye care professional about the different strategies about investing? 11:35 Is it best to have a team of investors or to have a professional to help navigate changing environments? 15:18 How do you, from a financial standpoint, help to weather those economic headwinds? What’s the best strategy for eye care professionals? 16:40 What do you think is the most important financial pearl in regards to financial planning and their financial future? 20:35 Segura’s final words 21:55 Jose Segura is a wealth management advisor and business exit planner for Wealth Advisory Group, LLC and a financial advisor with Park Avenue Securities, LLC. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at jose_segura@wagllc.com, or call 518-221-4832. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.
  • Eye Care Insider podcast

    AI and Telemedicine for the Retina Specialist

    26:32

    In this episode, I sit down with Kester Nahen, PhD, as we discuss the use of artificial intelligence and telemedicine among retina specialists. Nahen will also discuss Notal Vision’s ForseeHome device for monitoring and the company’s Home OCT artificial intelligence-enable platform for monitoring AMD. Intro :14 In this episode :21 About Dr. Nahen 1:24 The interview 1:42 The background of Kester Nahen 2:00 Nahen’s thoughts on the current state of telemedicine and artificial intelligence 5:10 Will artificial intelligence replace the clinical aspect of what we do? 7:42 About Notal Vision’s ForseeHome Device 9:30 The AMD criteria required for use of ForseeHome 11:54 As a result of COVID-19, has there been an increased interest in using ForseeHome? 13:15 What is the best way for ophthalmologists and eyecare providers to get more information about the ForseeHome program? 14:40 More details on Notal Vision’s Home OCT and will it really change and revolutionize the way retina specialists monitor patients? 16:00 What’s the status of the FDA approval process for the Home OCT? 21:10 What does Nahen think is the most important topic facing the ophthalmology industry today and what will be in the future? 23:05 Nahen’s final thoughts 25:30 Kester Nahen, PhD, is the chief executive officer at Notal Vision. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nahen is the CEO of Notal Vision. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Kom åt alla poddsändningar i gratisappen GetPodcast.

Prenumerera på dina favoritpoddar, lyssna på avsnitt offline och få spännande rekommendationer.

iOS buttonAndroid button